Glaxosmithkline Share News (GSK)

(For faster updates on individual market-movers, Eikon usersplease use search string "STXBZ US"; for more market insights,including options activity, ; for the Day Aheadnewsletter, http://link.reuters.com/mex49s; for the Morning NewsCall newsletter, http://link.reuters.com/nex49s) U.S. stock index e-mini futures were marginally up on Tuesday:Dow Jones industrial average futures were up 0.15percent at 17,003, S&P 500 futures were up 0.08 percentat 1,972.5 and Nasdaq 100 futures were up 0.21 percent at3,927.5.

** ROCKWOOD HOLDINGS INC, Monday close $75.7, +13.34pct premarket

** ALBEMARLE CORP, Monday close $72.62

Chemicals maker Albemarle Corp said it would buy rivalRockwood Holdings Inc for $6.2 billion to bulk up its lucrativespecialty chemical offerings. The combined company will haveleading positions across four high-margin businesses -lithium-based battery products, refinery catalysts, bromine andsurface treatment products, the companies said.

** LA JOLLA PHARMACEUTICAL CO, Monday close$10.85, +23.50 pct premarket

The drug developer reported positive pre-clinical data forLJPC-1010 in patients with non-alcoholic steatohepatitis, a formof liver inflammation. LJPC-1010 is a more potent form ofcompany's lead experimental drug, which is being tested for usein chronic kidney disease in a mid-stage study. La Jolla plansto file for investigational new drug application (IND) forLJPC-1010 and commence clinical development in the first half of2015. IND is reviewed by U.S. FDA to check if a product is safefor research subjects.

** LIONS GATE ENTERTAINMENT CORP, Monday close$28.73, +3.69 pct premarket

Chinese e-commerce giant Alibaba Group Holding and Lions Gate Entertainment Corp, the studio behind the'Hunger Games' films, will launch a subscription streamingservice in China, the firms said in a statement on Tuesday.

** GOPRO INC, Monday close $36.84, +6.35 pctpremarket

JMP Securities started coverage of the action camera maker'sstock with a "market outperform" rating and a price target of$60. "Our positive investment stance is predicated on the viewthat first mover and financial advantages will allow it tocapitalize on a multitude of under-penetrated and/or untappedopportunities," analyst Alex Gauna wrote in a note.

** OCEAN POWER TECHNOLOGIES INC, Monday close$1.53, -24.84 pct premarket

The company's unit, which develops systems to generateelectricity from ocean waves, Victorian Wave Partners, sent atermination notice to Australian Renewable Energy regardingfunding for renewable energy project, which it says is no longercommercially viable. Victorian Wave said it will stop all workon project and will not claim further funding and will returnreturn A$66.5 million ($62.3 million) grant received fromAustralian government in 2010 for project.

** CODEXIS INC, Monday close $1.41, +92.91 pctpremarket

The biofuel and biochemical maker's signed license deal withGlaxoSmithKline Plc, allowing British drugmaker to useCodexis's platform technology to develop novel enzymes for usein GSK's products. Codexis is eligible to get up to $25 millionover next two years, of which $6 million will be paid upfrontand rest will be paid on completion of technology transfermilestones

** COMERICA INC, Monday close $50.54, +2.89 pctpremarket

The bank reported higher-than-expected profit for secondquarter, as provision for credit losses fell 15 precent. Netincome rose 6 pct to $151 million. Total deposits increased 4pct to $53.4 billion.

** WOLVERINE WORLD WIDE INC, Monday close$26.45, +2.08 pct premarket

The casual and athletic footwear maker postedbetter-than-expected second-quarter profit and revenue helped byhigher sales. Wolverine said it would shut about 140 retailstores over the next 18 months. The maker of Caterpillar shoesreaffirmed full-year adjusted earnings forecast of $1.57 to$1.63 per share.

** STEMCELLS INC, Monday close $2.02, -4.95 pctpremarket

The drug developer said it will offer two institutionalinvestors about 11.3 million shares of common stock. 11.3million shares represented 6.2 pct of company's totaloutstanding shares as of March. The company to issue short-termwarrants for purchase of about 9.6 million additional shares ofcommon stock and plans to raise $20 million. The company willfund product development and capital expenditures with grossproceeds from the offering.

** MICHAEL KORS HOLDINGS LTD, Monday close$85.67, -3.53 pct premarket

At least three brokerages cut price targets on the luxuryhandbag maker's, citing higher discounts and slow sales in June. Barclays cut price target to $82 from $85, Citigroup to $98from $107 and Sterne Agee to $92 from $100 . "Store checksindicate a larger portion of products on sale (30 pct-50 pctoff) in June than what we had seen historically," Barclaysanalysts wrote in a note. "Elevated inventory levels, broaderdiscounting and investment needs may all combine to pressuremargins in the near future," Sterne Agee analyst Ike Boruchowsaid in a note.

** PLUG POWER INC, Monday close $4.18, +12.20 pctpremarket

FBR Capital Markets startED coverage on the fuel cellmaker's stock with "outperform" rating, price target of $8. PlugPower has successfully shifted to offering completehydrogen-based solutions from making just fuel cell power packsfor material handling systems, analysts said. Analysts expectnew order wins in United States, potential for expansion inEurope and rollouts of hydrogen delivery solutions.

** GOLDMAN SACHS GROUP INC, Monday close $167, +1.62pct premarket

Goldman Sachs reported 5 pct increase in second-quarterprofit, driven by higher revenue from its investing and lendingbusiness. The bank earned $1.95 billion, or 4.10 per share, inthe three months ended June 30. Analysts on average had expectedGoldman to report earnings of $3.05 per share, according toThomson Reuters I/B/E/S.

** CAMPBELL SOUP CO, Monday close $45.27, -2.50 pctpremarket

Analysts at Goldman Sachs cut its rating on the world'slargest soup maker's stock to sell from neutral, saying itanticipated a shortfall in earnings due to industry headwindsand lower promotional efficacy. The brokerage also cut its pricetarget to $39 from $41. Goldman Sachs said it expectedCampbell's earnings per share to fall next year and believed its2015 forecast could disappoint.

** VALERO ENERGY CORP, Monday close $49.93, -1.36pct premarket

The largest independent U.S. refining company Estimatedsecond-quarter profit from continuing operations of $1.10-$1.25per share, below the average analyst forecast of $1.39. Valerosaid it expects a loss of 12 cents per share from discontinuedoperations due to an asset retirement at the Aruba refinery.

** LORILLARD INC, >, Monday close $28.73, +3.69 pctpremarket

** REYNOLDS AMERICAN INC, Monday close $63.18

Camel cigarettes maker Reynolds American Inc said it wouldbuy rival Lorillard Inc in a cash-and-stock deal valued at $27.4billion, including net debt.

** MICROSOFT CORP, Monday close $42.14, +0.52 pctpremarket

Microsoft Corp is planning its biggest round of job cuts infive years as the software maker looks to integrate Nokia Oyj'sNOK1V.HE handset unit, Bloomberg reported, citing people withknowledge of the company's plans. The reductions, expected to beannounced as soon as this week, could be in the Nokia unit andthe parts of Microsoft that overlap with that business, as wellas in marketing and engineering, Bloomberg said.

** APOLLO EDUCATION GROUP, Monday close$29.57, -1.08 pct premarket

The U.S. Department of Education will review theadministration of federal student aid at the University ofPhoenix, Apollo Education Group said in a filing.

** JOHNSON & JOHNSON, Monday close $105.38

Johnson & Johnson reported sharply better-than-expectedquarterly revenue and earnings, fueled by strong sales of newerprescription drugs, including its Olysio treatment for hepatitisC.

** LEGGETT & PLATT, Monday close $33.67

The Furniture maker said it is looking to divest itsunderperforming store fixtures business and expects to take a$108 million goodwill impairment related to the business in thesecond quarter.

** ANTHERA PHARMACEUTICALS INC, Monday close$3.23, -0.93 pct premarket

Anthera said it acquired Sollpura, an investigationalpancreatic enzyme replacement therapy, from Eli Lilly. Anthera plans to sub-license all of Sollpura's rights to newlyformed unit, Alkira Therapeutics. Sollpura is potentialtreatment for patients with low levels of digestive enzymes. (Compiled by Sneha Banerjee in Bangalore; Edited by DonSebastian)